EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Probable Stevens–Johnson Syndrome During Taletrectinib Treatment After Crizotinib‐Related Rash in ROS1 ‐Positive Lung Cancer

Hirotoshi Yasui iD, Ryo Fukaura, Miyu Misaki, Souma Usui, Saho Katsumata, Ryo Niimi, Ko Ohara, Kaito Sano iD, Yasutaka Mori, Tomofumi Shibata, Yasutaka Fukui, Mitsuru Odate und 1 weitere

Respirology Case Reports · 2026-11 · 14 (11)

DOI: 10.1002/rcr2.70782 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Respirology Case Reports, online erschienen am 29.10.2026. Verfasst von Hirotoshi Yasui und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine Toyohashi Municipal Hospital Toyohashi Aichi Japan. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe cutaneous adverse reactions to taletrectinib, a next‐generation ROS1 inhibitor for ROS1‐rearranged non‐small cell lung cancer, remain poorly described. A 52‐year‐old woman with ROS1‐rearranged lung adenocarcinoma developed a Grade 3 rash during crizotinib therapy. After improvement, taletrectinib was initiated. On Day 21, conjunctival hyperaemia appeared, followed by high fever, neutropenia, widespread trunk‐dominant erythema, and lower‐lip mucosal involvement. Although epidermal detachment, a positive Nikolsky sign, and characteristic epidermal necrosis were absent, and typical target lesions were not documented during the acute phase, the clinical course was considered consistent with probable Stevens–Johnson syndrome. Fever and ocular symptoms rapidly improved after taletrectinib discontinuation and systemic corticosteroid therapy. Infection and human herpesvirus 6 (HHV‐6) reactivation were not identified, and ALDEN and Naranjo assessments supported a probable association with taletrectinib. During ROS1‐TKI therapy, fever and neutropenia should prompt consideration of severe cutaneous adverse reactions as well as infection.

Schlagwörter

Stichwörter der Autor:innen

CrizotinibROS1‐positive lung cancerStevens–Johnson syndromesevere cutaneous adverse reactiontaletrectinib

Autor:innen und Institutionen

  • Department of Respiratory Medicine Toyohashi Municipal Hospital Toyohashi Aichi Japan.
  • Department of Dermatology Toyohashi Municipal Hospital Toyohashi Aichi Japan.

ORCID-Profile: Hirotoshi Yasui, Kaito Sano, Yasushi Makino

Zitieren

APA

Yasui, H., Fukaura, R., Misaki, M., Usui, S., Katsumata, S., Niimi, R., Ohara, K., Sano, K., Mori, Y., Shibata, T., Fukui, Y., Odate, M., & Makino, Y. (2026). Probable Stevens–Johnson Syndrome During Taletrectinib Treatment After Crizotinib‐Related Rash in ROS1 ‐Positive Lung Cancer. Respirology Case Reports, 14(11). https://doi.org/10.1002/rcr2.70782

Vancouver

Yasui H, Fukaura R, Misaki M, Usui S, Katsumata S, Niimi R, et al. Probable Stevens–Johnson Syndrome During Taletrectinib Treatment After Crizotinib‐Related Rash in ROS1 ‐Positive Lung Cancer. Respirology Case Reports. 2026;14(11). doi:10.1002/rcr2.70782

BibTeX
@article{Yasui2026,
  author = {Yasui, Hirotoshi and Fukaura, Ryo and Misaki, Miyu and Usui, Souma and Katsumata, Saho and Niimi, Ryo and Ohara, Ko and Sano, Kaito and Mori, Yasutaka and Shibata, Tomofumi and Fukui, Yasutaka and Odate, Mitsuru and Makino, Yasushi},
  title = {Probable Stevens–Johnson Syndrome During Taletrectinib Treatment After Crizotinib‐Related Rash in ROS1 ‐Positive Lung Cancer},
  journal = {Respirology Case Reports},
  year = {2026},
  volume = {14},
  number = {11},
  doi = {10.1002/rcr2.70782}
}
Kostenlos starten →